本文選題：白芍總苷 + 地氯雷他定��； 參考：《遼寧中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的:采用meta分析的方法探討白芍總苷聯(lián)合地氯雷他定在慢性蕁麻疹治療中的療效。方法:在萬方數(shù)字化期刊全文數(shù)據(jù)庫(Wanfang data),相關(guān)期刊論文(CNKI),中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(CBM),維普中文科技期刊數(shù)據(jù)庫(VIP)及美國國立醫(yī)學(xué)圖書館(Pub Med)等數(shù)據(jù)庫進(jìn)行文獻(xiàn)檢索,在計(jì)算機(jī)的數(shù)據(jù)庫進(jìn)行文獻(xiàn)檢索的同時(shí),結(jié)合手工檢索圖書館館藏文獻(xiàn)并對學(xué)位論文等灰色文獻(xiàn)進(jìn)行檢索,文獻(xiàn)檢索的時(shí)間范圍為數(shù)據(jù)庫建庫日期開始至最后一次檢索時(shí)間2017年2月20日,在這個(gè)時(shí)間范圍內(nèi)檢索關(guān)于白芍總苷或白芍總苷膠囊聯(lián)合地氯雷他定治療慢性蕁麻疹的隨機(jī)對照臨床試驗(yàn)研究的文獻(xiàn)。按照Cochrane系統(tǒng)評價(jià)方法,采用RevMan 5.3軟件進(jìn)行Meta分析,比較白芍總苷聯(lián)合地氯雷他治療慢性蕁麻疹與地氯雷他定單藥治療慢性蕁麻疹在治療的總有效率、治療的痊愈率、顯效率、進(jìn)步率、無效率、經(jīng)過治療3個(gè)月后隨訪觀察到慢性蕁麻疹的疾病復(fù)發(fā)率、治療過程中及治療后患者發(fā)生的不良反應(yīng)的總發(fā)生率、口干、嗜睡、腹瀉等不良反應(yīng)的發(fā)生率等結(jié)局指標(biāo)的差異。結(jié)果:與采用地氯雷他定單藥治療的慢性蕁麻疹患者相比,采用白芍總苷聯(lián)合地氯雷他定治療的觀察組慢性蕁麻疹患者中患者獲得的總有效率顯著高于對照組(OR=4.53,95%置信區(qū)間為2.81-7.29,P0.00001),治愈率顯著高于對照組(OR=2.09,95%置信區(qū)間為1.45-3.01,P0.0001),顯效率顯著高于對照組(OR=1.55,95%置信區(qū)間=1.04-2.30,P0.05)。且與采用地氯雷他定單藥治療的慢性蕁麻疹患者相比,采用白芍總苷聯(lián)合地氯雷他定治療的觀察組慢性蕁麻疹患者中患者獲得的復(fù)發(fā)率顯著低于對照組(OR=0.20,95%置信區(qū)間為0.11-0.35,P0.00001),不良反應(yīng)總發(fā)生率顯著低于對照組(OR=0.56,95%置信區(qū)間為0.34-0.92,P=0.02),差異具有統(tǒng)計(jì)學(xué)意義。結(jié)論:白芍總苷聯(lián)合地氯雷他定對于慢性蕁麻疹具有顯著的療效。然而,由于本研究納入的文獻(xiàn)較少且納入的研究的樣本量較少,納入的研究在研究進(jìn)行時(shí)分組方法、盲法的實(shí)施等可能存在偏倚風(fēng)險(xiǎn)。導(dǎo)致本研究的結(jié)果可能需要更大樣本量的、高質(zhì)量的研究結(jié)果進(jìn)一步研究證實(shí)。
[Abstract]:Objective: to investigate the effect of total paeony glycoside combined with desloratadine in the treatment of chronic urticaria by meta. Methods: literature searches were carried out in Wanfang full text database of Wanfang, CNKI of China, CBMN of Chinese biomedical literature database, VIPB of Weipu Chinese scientific and technological journal and Pub Med. of the National Library of Medicine of the United States of America. At the same time of searching the literature in the database of computer, combining the manual retrieval of the library collection and the retrieval of grey documents, such as degree papers, etc., The time range of document retrieval is from the date of database construction to the time of the last retrieval, February 20, 2017. Literature on randomized controlled clinical trial of total glucoside of paeony or total glucoside of paeony combined with desloratadine in the treatment of chronic urticaria was searched within this time range. According to the evaluation method of Cochrane system and Meta analysis with RevMan 5.3 software, the total effective rate, cure rate and marked rate of total paeony glucoside combined with desloratazone in the treatment of chronic urticaria and desloratazone in the treatment of chronic urticaria were compared. After 3 months of treatment, the recurrence rate of chronic urticaria, the total incidence of adverse reactions during and after treatment, dry mouth, lethargy were observed. Incidence of adverse reactions such as diarrhea and other outcome indicators. Results: compared with patients with chronic urticaria treated with desloratazone, The total effective rate of patients with chronic urticaria in the observation group treated with total glucoside of paeony combined with desloratadine was significantly higher than that in the control group (4.53% 95% confidence interval = 2.81-7.29 P0.00001), and the cure rate was significantly higher than that in the control group (1.45-3.01P0.0001), and the cure rate was significantly higher than that in the control group (1.45-3.01P0.0001). It was significantly higher than that of the control group (1.55% 95% confidence interval, 1.04-2.30) (P 0.05). Compared with patients with chronic urticaria treated with desloratazone, The recurrence rate of patients with chronic urticaria in the observation group treated with total glucoside of paeony combined with desloratadine was significantly lower than that of the control group with 0.2095% confidence interval of 0.11-0.35 P0.00001, and the total incidence of adverse reactions was significantly lower than that of the control group of 0.56% 95% confidence interval. The difference was statistically significant. Conclusion: total glucosides of paeony combined with desloratadine are effective in the treatment of chronic urticaria. However, because the literature involved in this study is less and the sample size of the included research is less, the risk of bias may exist in the research included in the study, such as grouping method and the implementation of blind method. The results of this study may require greater sample size, and high-quality research results are further confirmed.
【學(xué)位授予單位】：遼寧中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R758.24

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 竺佳;黃巧玲;胡玉平;;白芍總苷聯(lián)合抗組胺藥治療慢性蕁麻疹療效和安全性的Meta分析[J];中國現(xiàn)代應(yīng)用藥學(xué);2016年11期

2 劉酉合;;抗敏湯治療慢性蕁麻疹隨機(jī)平行對照研究[J];實(shí)用中醫(yī)內(nèi)科雜志;2016年11期

3 柯仲成;楊楠;侯雪峰;王愛東;封亮;賈曉斌;;大鼠腸道菌群對芍藥苷體外代謝轉(zhuǎn)化的研究[J];中國中藥雜志;2016年20期

4 何淵民;楊艷;廖勇梅;黎昌強(qiáng);熊霞;;鹽酸左西替利嗪聯(lián)合孟魯斯特鈉及白芍總苷治療慢性自發(fā)性蕁麻疹44例臨床觀察[J];中國皮膚性病學(xué)雜志;2016年09期

5 袁秀澤;鄒盛勤;王曉剛;易劍峰;;白芍總苷在佐劑性關(guān)節(jié)炎大鼠與正常大鼠體內(nèi)的藥動(dòng)學(xué)差異[J];中國實(shí)驗(yàn)方劑學(xué)雜志;2016年20期

6 張哲奎;;慢性特發(fā)性蕁麻疹治療的臨床療效研究[J];大家健康(學(xué)術(shù)版);2016年10期

7 董淑英;;白芍總苷膠囊聯(lián)合枸地氯雷他定片治療慢性蕁麻疹臨床療效分析[J];航空航天醫(yī)學(xué)雜志;2016年03期

8 胡衛(wèi)彬;;地氯雷他定聯(lián)合白芍總苷對慢性蕁麻疹患兒血清干擾素-γ和白細(xì)胞介素-4的影響[J];中國實(shí)用醫(yī)刊;2016年04期

9 張麗;;白芍總苷膠囊與雷公藤多苷片聯(lián)合治療慢性特發(fā)性蕁麻疹患者的臨床效果[J];中國藥物經(jīng)濟(jì)學(xué);2015年S2期

10 王小艷;陳星宇;張洪英;;白芍總苷在皮膚科中的應(yīng)用進(jìn)展[J];中國中西醫(yī)結(jié)合皮膚性病學(xué)雜志;2015年04期

相關(guān)博士學(xué)位論文 前1條

1 王巧;芍藥質(zhì)量控制方法與白芍總苷藥物動(dòng)力學(xué)研究[D];沈陽藥科大學(xué);2005年

相關(guān)碩士學(xué)位論文 前2條

1 曹文利;白芍總苷基于代謝組學(xué)的保肝機(jī)理及體內(nèi)代謝研究[D];河北醫(yī)科大學(xué);2014年

2 任默蓮;白芍的化學(xué)成分與生物活性研究[D];沈陽藥科大學(xué);2009年

，

本文編號(hào)：1794190